Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders-Reference-Cited by-同舟云学术

Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders

Published:2009-02-12 Issue:6 Volume:65 Page:545-549
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Singh N.,Kumar L.,Meena R.,Velpandian T.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00228-009-0621-z.pdf

Reference22 articles.

1. Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340:1330–1340

2. Kumar L (2006) Chronic myelogenous leukemia (CML): an update. Nat Med J India 19:255–263

3. Peggs K, Mackinnon S (2003) Imatinib mesylate—the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 348:1048–1050

4. Gambacorti-Passerini CB, Gunby RH, Kaeda J (2003) Molecular mechanisms of resistance to imatinib in Philadelphia chromosome-positive leukaemias. Lancet Oncol 4:75–85

5. Druker BJ, Tamura S, Buchdunger E (1996) Effects of a selective inhibitors of the Abl tyrosinekinase on the growth of BCR–ABL positive cells. Nat Med 2:561–566

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of physiologically based pharmacokinetic modeling to understand real‐world outcomes in patients receiving imatinib for chronic myeloid leukemia;Pharmacology Research & Perspectives;2023-07-07

2. Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19;European Journal of Pharmaceutical Sciences;2023-05

3. The Application of Virtual Therapeutic Drug Monitoring to Assess the Pharmacokinetics of Imatinib in a Chinese Cancer Population Group;Journal of Pharmaceutical Sciences;2023-02

4. Real‐world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience;Pharmacology Research & Perspectives;2022-09-14

5. The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19;Trials;2022-02-16